echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Oncol: olaparib monotherapy may be expected to treat early-stage triple-negative breast cancer

    Ann Oncol: olaparib monotherapy may be expected to treat early-stage triple-negative breast cancer

    • Last Update: 2021-06-19
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    News April 25, 2021 // --PAPR inhibitors (PARPi) have proven their anti-tumor efficacy in breast cancer patients with germline BRCA1/2 (gBRCA1/2) mutations, although PARPi monotherapy is not effective It treats patients with metastatic triple-negative breast cancer (TNBC) carrying wild-type BRCA1/2, but the researchers speculate that PARPi may be effective for patients with primary TNBCs who have not previously received chemotherapy


    Annals of Oncology Olaparib monotherapy may be expected as the main treatment for non-selective triple-negative breast cancer patients; and targeted therapy for early-stage breast cancer may provide help to significantly increase the success rate of treatment


    Image source: https:// (Poly ADP-ribose polymerase) inhibitor is a targeted therapy suitable for many types of cancer, including prostate cancer, ovarian cancer and rare breast cancer


    PARP (Poly ADP-ribose polymerase) inhibitor is a targeted therapy suitable for many types of cancer, including prostate cancer, ovarian cancer and rare breast cancer


    The researchers said that of the 32 patients treated, 18 (56%) patients were effective on olaparib monotherapy, which was manifested as tumor regression; most importantly, 16 of the 18 responders All of them showed special molecular markers (gene mutations or so-called epigenetic modifications), which may help predict the benefits of genes involved in the DNA repair process, and only 4 of the 14 non-responders were Such a situation


    Of the 32 patients who received treatment, 18 (56%) patients were effective on olaparib monotherapy, which was manifested by regression of tumors; most importantly, 16 of the 18 responders showed signs of Special molecular markers (gene mutations or so-called epigenetic modifications) may help predict the benefits of genes involved in the DNA repair process, which is the case for only 4 of the 14 non-responders


    Summary of the research group of the PETREMAC new auxiliary trial


    Image source: HP Eikesdal, et al.


    Annals of Oncology

    However, among patients who did not carry this germline mutation (ie, patients who would normally be excluded from PARP inhibitor treatment), 54% (14/26) of the patients responded to the treatment.


    The researchers believe that the results of this study challenge the previous dogmatic view that PARP inhibition may not have an effect on cancer patients who do not carry germline mutations.


    OncoPrint list of homologous recombination gene mutations in triple-negative breast cancer patients (N=32) from the PETREMAC clinical trial


    Image source: HP Eikesdal, et al.


    Annals of Oncology

    In summary, in addition to germline homologous recombination mutations, olaparib therapy can produce a higher clinical response rate in the treatment of triple-negative breast cancer with homologous recombination defects


    Although previous studies have found that PAPR inhibition has no therapeutic benefit for advanced breast cancer, the results of this article have found that therapies that have no therapeutic benefit in the treatment of advanced breast cancer may potentially treat early-stage breast cancer


    Original source:

    HP Eikesdal, S.


    HP Eikesdal, S.
    Yndestad, A.
    Elzawahry, et al.
    Olaparib monotherapy as primary treatment in unselected triple negative breast cancer , Annals of Oncology (2020).
    DOI:10.
    1016/j.
    annonc.
    2020.
    11.
    009 Olaparib monotherapy as primary treatment in unselected triple negative breast cancer Annals of Oncology
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.